Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2024-07-12
- Lead Sponsor
- Sunnybrook Health Sciences Centre
- Target Recruit Count
- 63
- Registration Number
- NCT04624906
- Locations
- 🇨🇦
McGill University Health Centre, Montréal, Quebec, Canada
🇨🇦QEII Health Sciences Centre, Halifax, Nova Scotia, Canada
🇨🇦CHU de Quebec - University Laval, Laval, Quebec, Canada
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 23
- Registration Number
- NCT04587687
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL
- Conditions
- Interventions
- First Posted Date
- 2020-08-17
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 42
- Registration Number
- NCT04515238
- Locations
- 🇩🇪
Onkologische Schwerpunktpraxis, Esslingen, Germany
🇩🇪Hamatologische/Onkologische Gemeinschaftspraxis, Augsburg, Germany
🇩🇪Universitätsklinik Köln, Köln, Germany
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 37
- Registration Number
- NCT04510636
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
- Conditions
- Interventions
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 166
- Registration Number
- NCT04285567
- Locations
- 🇫🇷
CHU de Caen, Institut d'Hématologie de Basse-Normandie, Caen, France
🇫🇷Hopital Robert Debre; Hematologie Clinique, Reims, France
🇺🇸Oncology & Hematolgy Associates of SW Va Inc. - Roanoke, Roanoke, Virginia, United States
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
- Conditions
- Interventions
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Tessa Therapeutics
- Target Recruit Count
- 97
- Registration Number
- NCT04268706
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies
- Conditions
- Interventions
- First Posted Date
- 2020-01-29
- Last Posted Date
- 2023-10-26
- Lead Sponsor
- Fate Therapeutics
- Target Recruit Count
- 98
- Registration Number
- NCT04245722
- Locations
- 🇺🇸
The University of Chicago, Chicago, Illinois, United States
🇺🇸University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).
- Conditions
- Interventions
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 42
- Registration Number
- NCT04236141
- Locations
- 🇨🇳
Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University), Nanjing City, China
🇨🇳Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan City, China
🇨🇳West China Hospital, Sichuan University, Chengdu, China
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
- Conditions
- Interventions
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04223765
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.